Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Rheumatology Reports

01.05.2014 | RHEUMATOID ARTHRITIS (LW MORELAND, SECTION EDITOR)

Preclinical Rheumatoid Arthritis (Autoantibodies): An Updated Review

verfasst von: Kevin D. Deane

Erschienen in: Current Rheumatology Reports | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Multiple studies demonstrate that there is a period of development of rheumatoid arthritis (RA) during which there are elevations of disease-related biomarkers, including autoantibodies, in the absence of and prior to the development of RA; this period can be termed ‘preclinical RA’. These ‘preclinical’ autoantibodies including rheumatoid factor and antibodies to citrullinated protein antigens, and more recent studies have also identified additional autoantibodies and a wide range of inflammatory biomarkers. These findings in conjunction with established and emerging data about genetic and environmental risk factors for RA support a model of disease development where certain factors lead to an initial triggering of RA-related autoimmunity that expands over time to the point where symptomatic arthritis classifiable as RA develops. Herein will be reviewed updates in the field, as well as a discussion of current limitations of our understanding of preclinical RA, and potential future directions for study.
Literatur
1.
Gerlag DM, Raza K, van Baarsen LG, et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis. 2012;71:638–41.PubMedCentralPubMedCrossRef
2.
Demoruelle MK, Deane K. Antibodies to Citrullinated Protein Antigens (ACPAs): Clinical and Pathophysiologic Significance. Curr Rheumatol Rep 2011.
3.
Demoruelle MK, Parish MC, Derber LA, et al. Anti-cyclic citrullinated peptide assays differ in subjects at elevated risk for rheumatoid arthritis and subjects with established disease. Arthritis Rheum 2013.
4.
Aho K, Heliovaara M, Maatela J, Tuomi T, Palosuo T. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol. 1991;18:1282–4.PubMed
5.
Aho K, Palosuo T, Heliovaara M, Knekt P, Alha P, von Essen R. Antifilaggrin antibodies within "normal" range predict rheumatoid arthritis in a linear fashion. J Rheumatol. 2000;27:2743–6.PubMed
6.
Aho K, von Essen R, Kurki P, Palosuo T, Heliovaara M. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol. 1993;20:1278–81.PubMed
7.
del Puente A, Knowler WC, Pettitt DJ, Bennett PH. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum. 1988;31:1239–44.PubMedCrossRef
8.
Silman AJ, Hennessy E, Ollier B. Incidence of rheumatoid arthritis in a genetically predisposed population. Br J Rheumatol. 1992;31:365–8.PubMedCrossRef
9.
Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741–9.PubMedCrossRef
10.
Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50:380–6.PubMedCrossRef
11.
Majka DS, Deane KD, Parrish LA, et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis. 2008;67:801–7.PubMedCentralPubMedCrossRef
12.
Chibnik LB, Mandl LA, Costenbader KH, Schur PH, Karlson EW. Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis. J Rheumatol. 2009;36:706–11.PubMedCentralPubMedCrossRef
13.
Jorgensen KT, Wiik A, Pedersen M, et al. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case–control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis. 2008;67:860–6.PubMedCrossRef
14.
Rantapaa-Dahlqvist S, Boman K, Tarkowski A, Hallmans G. Up regulation of monocyte chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin M rheumatoid factor positive subjects precedes onset of inflammatory response and development of overt rheumatoid arthritis. Ann Rheum Dis. 2007;66:121–3.PubMedCentralPubMedCrossRef
15.
Nielen MM, van Schaardenburg D, Reesink HW, et al. Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis. Ann Rheum Dis. 2006;65:535–7.PubMedCentralPubMedCrossRef
16.
Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa DS. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010;62:383–91.PubMed
17.
Deane KD, O'Donnell CI, Hueber W, et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis & Rheumatism. 2010;62:3161–72.CrossRef
18.
Aho K, Palosuo T, Knekt P, Alha P, Aromaa A, Heliovaara M. Serum C-reactive protein does not predict rheumatoid arthritis. J Rheumatol. 2000;27:1136–8.PubMed
19.
Karlson EW, Chibnik LB, Tworoger SS, et al. Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthritis Rheum. 2009;60:641–52.PubMedCentralPubMedCrossRef
20.
van Baarsen LG, Bos WH, Rustenburg F, et al. Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis. Arthritis Rheum. 2010;62:694–704.PubMedCrossRef
21.
Lubbers J, Brink M, van de Stadt LA, et al. The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Ann Rheum Dis. 2013;72:776–80.PubMedCrossRef
22.
Bos WH, Wolbink GJ, Boers M, et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis. 2010;69:490–4.PubMedCrossRef
23.•
Brink M, Hansson M, Mathsson L, et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum 2013. Uses ACPA arrays to demonstrate epitope spreading in preclinical RA; this may be a fundamental issue in how autoimmunity transforms from asymptomatic stage to clinically apparent disease.
24.
van de Stadt LA, van der Horst AR, de Koning MH, et al. The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis. 2011;70:128–33.PubMedCrossRef
25.•
Sokolove J, Bromberg R, Deane KD, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One. 2012;7:e35296. Presents methods to use multiple biomarkers to predict both likelihood and timing of future RA; these are important concepts in personalized medicine. PubMedCentralPubMedCrossRef
26.
Suwannalai P, van de Stadt LA, Radner H, et al. Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum. 2012;64:1323–8.PubMedCrossRef
27.•
Shi J, van de Stadt LA, Levarht EW, et al. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum. 2013;65:911–5. Describes a novel autoantibody system to carbamylated proteins in preclinical RA. PubMedCrossRef
28.
Shi J, van de Stadt LA, Levarht EW, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis 2013.
29.
van de Stadt LA, de Vrieze H, Derksen NI, et al. Antibodies to IgG4 hinge can be found in Rheumatoid Arthritis patients during all stages of disease and may exacerbate chronic antibody-mediated inflammation. Arthritis Rheum 2013.
30.
Kolfenbach JR, Deane KD, Derber LA, et al. Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum 2010.
31.
Rombouts Y, Ewing E, van de Stadt LA, et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis 2013.
32.
Ercan A, Cui J, Chatterton DE, et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2010;62:2239–48.PubMedCrossRef
33.
van de Stadt LA, Witte BI, Bos WH, van Schaardenburg D. A prediction rule for the development of arthritis in seropositive arthralgia patients. Ann Rheum Dis 2012.
34.
Kolfenbach JR, Deane KD, Derber LA, et al. A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. Arthritis Rheum. 2009;61:1735–42.PubMedCentralPubMedCrossRef
35.
Demoruelle MK, Weisman MH, Simonian PL, et al. Brief Report: Airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: Early injury or initiating site of autoimmunity? Arthritis Rheum. 2012;64:1756–61.PubMedCentralPubMedCrossRef
36.
Young KA, Deane KD, Derber LA, et al. Relatives without rheumatoid arthritis show reactivity to anti-citrullinated protein/peptide antibodies that are associated with arthritis-related traits: studies of the etiology of rheumatoid arthritis. Arthritis Rheum. 2013;65:1995–2004.PubMedCrossRef
37.
Hughes-Austin JM, Deane KD, Derber LA, et al. Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA). Ann Rheum Dis. 2013;72:901–7.PubMedCrossRef
38.
El-Gabalawy HS, Robinson DB, Hart D, et al. Immunogenetic risks of anti-cyclical citrullinated peptide antibodies in a North American Native population with rheumatoid arthritis and their first-degree relatives. J Rheumatol. 2009;36:1130–5.PubMedCrossRef
39.
Ioan-Facsinay A, Willemze A, Robinson DB, et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum. 2008;58:3000–8.PubMedCrossRef
40.
El-Gabalawy HS, Robinson DB, Smolik I, et al. Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients. Arthritis Rheum 2012.
41.
Kim SK, Bae J, Lee H, Kim JH, Park SH, Choe JY. Greater prevalence of seropositivity for anti-cyclic citrullinated peptide antibody in unaffected first-degree relatives in multicase rheumatoid arthritis-affected families. Korean J Intern Med. 2013;28:45–53.PubMedCentralPubMedCrossRef
42.
Barra L, Scinocca M, Saunders S, et al. Anti-citrullinated protein antibodies (ACPA) in unaffected first degree relatives of rheumatoid arthritis patients. Arthritis Rheum 2013.
43.
Arlestig L, Mullazehi M, Kokkonen H, Rocklov J, Ronnelid J, Dahlqvist SR. Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden. Ann Rheum Dis. 2012;71:825–9.PubMedCentralPubMedCrossRef
44.
van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis. 2010;69:1554–61.PubMedCrossRef
45.
Deane KD, Norris JM, Holers VM. Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum Dis Clin North Am. 2010;36:213–41.PubMedCentralPubMedCrossRef
46.
Sokolove J, Zhao X, Chandra PE, Robinson WH. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor. Arthritis Rheum. 2011;63:53–62.PubMedCentralPubMedCrossRef
47.
Tuomi T, Aho K, Palosuo T, Kaarela K, von Essen R, Isomaki H. Seronegative rheumatoid arthritis in an eight-year longitudinal study. Scand J Rheumatol Suppl. 1987;67:67–9.PubMed
48.
Alarcon GS, Koopman WJ, Acton RT, Barger BO. Seronegative rheumatoid arthritis. A distinct immunogenetic disease? Arthritis Rheum. 1982;25:502–7.PubMedCrossRef
49.
Hitchon CA, El-Gabalawy HS. Immune features of seronegative and seropositive arthritis in early synovitis studies. Curr Opin Rheumatol. 2002;14:348–53.PubMedCrossRef
50.
Whiting PF, Smidt N, Sterne JA, et al. Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med. 2010;152(456–64):W155–66.
51.
Wagner CA, Sokolove J, Lahey LJ, et al. Identification of anticitrullinated protein antibody reactivities in a subset of anti-CCP-negative rheumatoid arthritis: association with cigarette smoking and HLA-DRB1 'shared epitope' alleles. Ann Rheum Dis 2014.
52.
Barra L, Bykerk V, Pope JE, et al. Anticitrullinated Protein Antibodies and Rheumatoid Factor Fluctuate in Early Inflammatory Arthritis and Do Not Predict Clinical Outcomes. J Rheumatol 2013.
53.
Arkema EV, Goldstein BL, Robinson W, et al. Anti-citrullinated peptide autoantibodies, human leukocyte antigen shared epitope and risk of future rheumatoid arthritis: a nested case–control study. Arthritis Res Ther. 2013;15:R159.PubMedCentralPubMedCrossRef
54.
Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med. 2006;119(503):e1–9.PubMed
55.
Oliver JE, Silman AJ. Risk factors for the development of rheumatoid arthritis. Scand J Rheumatol. 2006;35:169–74.PubMedCrossRef
56.
Ebringer A. Rheumatoid arthritis and proteus. London: Springer-Verlag; 2012.CrossRef
57.
Wegner N, Wait R, Sroka A, et al. Peptidylarginine deiminase from porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase: Implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 2010.
58.
Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife. 2013;2:e01202.PubMedCentralPubMedCrossRef
59.
Scher JU, Ubeda C, Equinda M, et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum 2012.
60.
Snir O, Widhe M, Hermansson M, et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum. 2010;62:44–52.PubMedCrossRef
61.
Gent YY, Voskuyl AE, Kloet RW, et al. Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: findings of a prospective pilot study. Arthritis Rheum. 2012;64:62–6.PubMedCrossRef
62.
van de Sande MG, de Hair MJ, van der Leij C, et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis. 2011;70:772–7.PubMedCrossRef
63.
van de Stadt LA, Bos WH, Meursinge Reynders M, et al. The value of ultrasonography in predicting arthritis in auto-antibody positive arthralgia patients: a prospective cohort study. Arthritis Res Ther. 2010;12:R98.PubMedCentralPubMedCrossRef
64.
Willis VC, Demoruelle MK, Derber LA, et al. Sputa autoantibodies in patients with established rheumatoid arthritis and subjects at-risk for future clinically apparent disease. Arthritis Rheum 2013.
65.
Mikuls TR, Thiele GM, Deane KD, et al. Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis and rheumatism. 2012;64:3522–30.PubMedCrossRef
66.
Scher JU, Ubeda C, Equinda M, et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum. 2012;64:3083–94.PubMedCentralPubMedCrossRef
67.
Wegner N, Lundberg K, Kinloch A, et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev. 2010;233:34–54.PubMedCrossRef
68.
Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife 2013;2.
69.
Arend WP, Firestein GS. Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat Rev Rheumatol. 2012;8:573–86.PubMedCrossRef
70.•
Bellatin MF, Han M, Fallena M, et al. Production of autoantibodies against citrullinated antigens/peptides by human B cells. J Immunol. 2012;188:3542–50. Novel study that identifies specific B and T cells that are reactive to citrullinated antigens; may represent next generation of testing to identify immune responses. PubMedCrossRef
71.•
Law SC, Street S, Yu CH, et al. T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles. Arthritis Res Ther. 2012;14:R118. Novel study that identifies specific B and T cells that are reactive to citrullinated antigens; may represent the next generation of testing to identify immune responses. PubMedCentralPubMedCrossRef
72.•
Szarka E, Babos F, Magyar A, et al. Recognition of new citrulline-containing peptide epitopes by autoantibodies produced in vivo and in vitro by B cells of rheumatoid arthritis patients. Immunology. 2014;141:181–91. Novel study that identifies specific B and T cells that are reactive to citrullinated antigens; may represent the next generation of testing to identify immune responses. PubMedCrossRef
73.
74.
Dye JR, Ullal AJ, Pisetsky DS. The role of microparticles in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Scand J Immunol. 2013;78:140–8.PubMedCrossRef
75.
Bos WH, Dijkmans BA, Boers M, van de Stadt RJ, van Schaardenburg D. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann Rheum Dis. 2010;69:571–4.PubMedCrossRef
76.•
Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease (PRAIRI). at http://​www.​trialregister.​nl/​trialreg/​admin/​rctview.​asp?​TC=​2442.) PRAIRI study: Dutch study using rituximab to prevent the future onset of RA in subjects at-risk based on elevations of RA-related autoantibodies; results may help to change the paradigm of how RA is managed.
77.
Sosenko JM, Skyler JS, Palmer JP, et al. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care. 2013;36:2615–20.PubMedCrossRef
78.
Skyler JS, Greenbaum CJ, Lachin JM, et al. Type 1 Diabetes TrialNet–an international collaborative clinical trials network. Ann N Y Acad Sci. 2008;1150:14–24.PubMedCentralPubMedCrossRef
Metadaten
Titel
Preclinical Rheumatoid Arthritis (Autoantibodies): An Updated Review
verfasst von
Kevin D. Deane
Publikationsdatum
01.05.2014
Verlag
Springer US
Erschienen in
Current Rheumatology Reports / Ausgabe 5/2014
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-014-0419-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise